Please assess the completion status of the following clinical trial:

Trial Title: Candesartan Versus Propranolol for Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 65 years~* retrospectively have ≥ 2 migraine attacks per month during the last 3 months~* during the baseline period have ≥ 2 migraine attacks~* debut of migraine at least one year prior to inclusion~* start of migraine before age 50 years.~Exclusion Criteria:~* interval headache not distinguishable from migraine~* chronic tension-type headache or other headache occurring on ≥ 15 days/month~* pregnancy, nursing or inability to use contraceptives~* heart conduction block on ECG or significant ECG abnormality on inclusion~* heart rate \< 54 after 3 minutes rest~* previous or present asthma, diabetes; decreased hepatic or renal function~* hypersensitivity to active substance~* history of angioneurotic edema~* significant psychiatric illness~* use of daily migraine prophylactics less than 4 weeks prior to start of study~* having tried ≥ 3 prophylactic drugs against migraine during the last 10 years~* previous use of propranolol or candesartan in adequate doses~* previous discontinuation of either Atacand or Inderal Retard (or another beta blocker) due to side effects~* current use of antihypertensive medication~* require use of rizatriptan (Maxalt) 10 mg tabl.~* subjects requiring detoxification from acute medication (ergotamines, opioids)~* patients who consistently fail to respond to any acute migraine medication~* patients with alcohol or illicit drug dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 Candesartan (Type: EXPERIMENTAL): None
- 2 propranolol (Type: ACTIVE_COMPARATOR): None
- 3 Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).